Expect downward pressure on TVRD shares as the shelf overhang materializes. Monitor for prospectus supplements signaling actual share sales, particularly under the ATM facility. Consider short-term bearish positioning but be cautious of volatility from potential positive clinical news, as the company is a pre-revenue biotech.
Price Chart
Executive Summary
Tvardi Therapeutics' S-3 registration statement has been declared effective, allowing the company to sell up to $200 million in securities, including a $12.5 million ATM offering via JonesTrading. With a market cap of only $37 million, this shelf represents a massive dilution overhang, posing significant risk to existing shareholders.
Key Facts
- S-3 registration effective 2026-05-12, permitting sale of up to $200M in common stock, preferred stock, debt securities, and warrants.
- Includes a $12.5M at-the-market (ATM) offering through JonesTrading Institutional Services LLC.
- Company market cap is $37M; the shelf size is over 5x the current market cap, indicating extreme potential dilution.
- The S-3 was originally filed on 2026-05-01, and this EFFECT notice confirms its activation.
Financial Impact
Potential dilution of up to 540% of current market cap if the full $200M shelf is utilized; immediate overhang even without sales.
Risk Factors
- Massive dilution from future offerings could severely depress stock price.
- Limited positive catalysts to offset the overhang; company's clinical-stage status adds binary risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001593 |
| Document: 9999999995-26-001593-index.html | 9999999995-26-001593 |
| Document: 9999999995-26-001593.txt | 9999999995-26-001593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8420 (+54.73%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8420 (−55.68%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8420 (−55.68%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8420 (−59.90%) |
Jul 7, 2026 15w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8420 (−72.84%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8420 (+78.74%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8420 (+78.68%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8420 (−79.86%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8420 (−72.84%) |
Mar 31, 2026 29w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8420 (−71.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers